Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)

The Role of the Cystic Fluid Interleukins 1,8, & 10 and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03178812

Enrollment

Registered

2017-06-07

Start date

2017-06-30

Completion date

2019-06-30

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

This study aims to find a correlation between cytokines levels and malignancy potential of different cystic types.

Interventions

PROCEDUREEUS with fine-needle aspiration of pancreatic cyst

EUS with fine-needle aspiration

DIAGNOSTIC_TESTLaboratory Blood test

Laboratory Blood Test

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

One arm containing patients with pancreatic lesion and one control group arm of healthy volunteers

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with pancreatic cyst

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Prediction of malignant potential of pancreatic cyst by measuring Interleukin levels	Two years	Interleukin 1,8,10 will be measured quantitatively by an enzyme-linked immunosorbent assay. The same interleukins levels will be measured in serum of same patients and control group. Results will enable classification of cysts to either high or low risk malignancy potential.
Prediction of malignant potential of pancreatic cyst by measuring TNF levels	Two years	TNF levels will be measured quantitatively by an enzyme-linked immunosorbent assay. The same TNF levels will be measured in serum of same patients and control group. Results will enable classification of cysts to either high or low risk malignancy potential.

Countries

Israel

Contacts

Primary ContactYael Kopelman, MD

yaelk@hy.health.gov.il972-50-6246840

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026